Strategic expansion Reflow Medical has recently expanded its footprint with a new Europe presence, including Germany, signaling a regional growth push that sales teams can leverage to pursue hospital networks and distributors in Western Europe.

Product portfolio momentum The launch of next generation Cora Flex and Cora Force Torqueable Microcatheters and the Spur Stent System demonstrates a continuous product cadence, offering upsell and cross-sell opportunities with existing cardiovascular practices and trials to expand adoption.

Clinical evidence Recent presentations at EuroPCR and SIR showcasing six and twelve month DEEPER REVEAL/DEEPER CORONARY results provide talking points for evidence-based selling, enabling clinics to justify procurement through demonstrated outcomes.

Global collaboration Participation in international events such as PAIRS 2025 and partnerships with other vascular innovators indicate a network-ready stance; leverage these connections to access new distributor channels and hospital accounts.

Financial opportunity Mid-market revenue range with modest external funding suggests room for channel partnerships, bundled solutions, and strategic investments to accelerate market penetration in both the US and EU.